NervGen Pharma Common stock Return on Equity

NervGen Pharma Common stock (NGEN) currently reports a ROE of -390.39%. That is below the Healthcare sector average of -100.59%. Use the charts on this page to explore NervGen Pharma Common stock's ROE history and peer comparisons.

NervGen Pharma Common stock's ROE of -390.39% is lower than the Healthcare sector average of -100.59%. That is roughly 288.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but NervGen Pharma Common stock's current -390.39% should be judged against Healthcare norms (sector average: -100.59%) and against NGEN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -390.39%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for NervGen Pharma Common stock, and consider following NGEN for alerts when major investors trade the stock.

NervGen Pharma Common stock is classified in the Healthcare sector. On ROE, it currently shows -390.39% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NGEN with unrelated industries.